Drug Approvals Monthly Update: March 2024 Traditional New drugs 3/04/2024 clobetasol propionate 0.05% The FDA approved the first clobetasol propionate ophthalmic formulations. The 0.05% suspension...

PUBLICATIONS FDA Decisions Expected: August 2025 Your monthly synopsis of new drugs expected to hit the market All brand names are property of their respective owners. References Press release:...

In the latest episode of the “Pharmacy Friends” podcast, hear from Prime Therapeutics experts about how the fast-moving pipeline is changing how patients, providers and payers prepare for...

Polaris is awaiting an FDA decision for pegargiminase, an arginine degrading enzyme, for the treatment of malignant pleural mesothelioma (MPM) with non-epithelioid histology. The FDA granted the...

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Learn with Biosimilar Basics. Part 1 starts with an overview of biosimilar products, sharing what biosimilar drugs are and the difference vs generic drugs.

Journal of Managed Care & Specialty Pharmacy (JMCP)

Unlock high-touch outreach Help members and their prescribers make better decisions about medicines through this clinical intelligence hub that delivers actionable insights, flexible levels of data...

In the latest episode of the “Pharmacy Friends” podcast, hear more about what faster drug decisions could mean for evidence review, affordability assessment and implementation planning

From research posters and education sessions to the Pharmacy Friends podcast, Prime has you covered on the latest managed care pharmacy insights

Prime Therapeutics clinical experts shared insights on the specialty drug pipeline at recent industry event

A roundup of Prime's award-winning presentations and insights at AMCP Annual Meeting in Houston

In the latest episode of the “Pharmacy Friends” podcast, join Prime’s research team for a preview of the industry-leading and award-winning research that will be presented at flagship industry event

Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model

Learn with Biosimilar Basics. Part 2 covers biosimilar naming conventions and other nomenclature including common drug pipeline content acronyms.

In this episode, Prime/MRx clinicians — along with special guests — discuss the hottest topics covered at the Academy of Managed Care Pharmacy (AMCP)'s 2024 Annual Meeting in New Orleans

Managed Healthcare Executive

USA Today

Reuters

Insider

CNBC

Formulary Watch

Star Tribune

Business Insider

Endpoint News

Reuters

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

Reuters

Reuters

NBC News: Patients weren't asked why they quit taking the weight loss drugs

Reuters

Prime Therapeutics’ Clinical Insights is your trusted resource for timely, evidence based perspectives on emerging therapies and managed care strategy. The Summer 2025 issue focuses on metabolic...

A roundup of Prime's award-winning presentations and insights at AMCP Nexus in National Harbor, Maryland

In the U.S. Food and Drug Administration (FDA)’s latest annual report of drug approvals, the agency shared it approved a total of 46 novel drugs in 2025. Here’s how that stacks up against years...

Industry experts share new insights from PBM industry, including GLP-1 weight-loss drugs, biosimilars and rising pharmaceutical costs

A roundup of Prime's award-winning presentations and insights at AMCP 2026 in Nashville, Tennessee

Novartis submitted an application to the FDA in 2Q 2025 for an intrathecal formulation (OAV101IT) of their one-time gene therapy onasemnogene abeparvovec (OAV101IT) for the treatment of spinal...

New indications for approved gene / cell therapy products - 2024 Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* fidanacogene elaparvovec-dzkt Beqvez™...

Maryam Tabatabai, PharmD, associate vice president of clinical information, shares more about how cell and gene therapies are transforming the treatment landscape, and how payers and providers can...

Hear some of the latest insights from the annual managed care pharmacy event, where Prime Therapeutics clinical and health outcomes teams presented leading research findings

Annual conference gathers 2,500+ managed care leaders to discuss complex health care issues.

Clinical deep dive Disease state overview SMA is a rare, debilitating, hereditary disease characterized by progressive motor function decline and muscular atrophy. Most commonly, SMA results from a...

A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the use of GLP-1 medications to treat obesity when paired...

Identifying and managing diabetes and weight loss therapies earns AMCP platinum award

Drug Approvals Monthly Update: February 2024 Specialty New drugs 2/16/2024 Amtagvi™ (lifileucel) The United States (U.S.) Food and Drug Administration (FDA) approved the first-in-class...

Drug Approvals Monthly Update: January 2024 Traditional New drugs 1/05/2024 Zelsuvmi™ (berdazimer): The FDA approved Zelsuvmi for the topical treatment of molluscum contagiosum (MC) in adult and...

Zolgensma, which was FDA approved in May 2019, is administered as an intravenous (IV) infusion, with dosing based on patient weight, in pediatric patients under 2 years of age with SMA caused by...

Home Newsroom Custom Content Publications Drug Approvals Drug Approvals Monthly Update: September 2024 1. ADvocate 1 and 2 trials: https://pubmed.ncbi.nlm.nih.gov/36920778/ 2. ADhere trial:...

Read Drug Approval Update Specialty New drugs 06/06/2024 Rytelo™ (imetelstat) The FDA approved the first-in-class oligonucleotide telomerase inhibitor, Rytelo, for the treatment of adults with low-...

Specialty New drugs 3/18/2024 Lenmeldy™ (atidarsagene autotemcel) Lenmeldy is an autologous hematopoietic stem cell-based gene therapy by Orchard Therapeutics, which was FDA approved for the...

Read Drug Approval Update Specialty New drugs 04/22/2024 Anktiva® (nogapendekin alfa inbakicept-pmln) The FDA approved Anktiva for use in combination with Bacillus Calmette-Guérin (BCG) for the...

Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status Tividenofusp alfa (DNL310) AstraZeneca IV a fusion protein ERT...

Editor-In-Chief: Maryam Tabatabai, PharmD Executive Editor: Anna Schreck Bird, PharmD Deputy Editors: Erik Hamel, PharmD; Olivia Pane, PharmD, CDCES A retrospective propensity score-matched cohort...

Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status DNL126 Denali Therapeutics  IV SGSH RT using ETVto deliver SGSH...

Want more information on this topic and more from our KOLs? On June 15, 2025, Sarepta, the manufacturer of Elevidys, issued a press release that announced a safety update for Elevidys and steps to...

Editorial team The American College of Physicians (ACP) has released a clinical practice guideline on use of pharmacological treatment for prevention of episodic migraine, defined as one to 14...

Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* aprocitentan Tryvio® Idosia Difficult-to-control or resistant hypertension Oral March budesonide Eohilia™...

cover image for Summer 2025 Issue: Clinical Insights – MASH A new era in liver health: Treatment innovation, payer strategy, and pipeline momentum Prime Therapeutics...

Critical updates in an ever-changing environment.